CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
4.25
7.21%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Vanda Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 4.58
Open* 4.44
1-Year Change* -30.08%
Day's Range* 4.19 - 4.44
52 wk Range 3.30-8.15
Average Volume (10 days) 1.07M
Average Volume (3 months) 19.08M
Market Cap 212.29M
P/E Ratio 18.24
Shares Outstanding 57.53M
Revenue 211.85M
EPS 0.20
Dividend (Yield %) N/A
Beta 0.69
Next Earnings Date Feb 6, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 4, 2024 4.25 -0.35 -7.61% 4.60 4.61 4.19
Mar 1, 2024 4.58 0.10 2.23% 4.48 4.69 4.43
Feb 29, 2024 4.45 -0.04 -0.89% 4.49 4.56 4.43
Feb 28, 2024 4.45 -0.10 -2.20% 4.55 4.60 4.43
Feb 27, 2024 4.57 -0.03 -0.65% 4.60 4.74 4.57
Feb 26, 2024 4.54 0.16 3.65% 4.38 4.57 4.38
Feb 23, 2024 4.42 0.15 3.51% 4.27 4.43 4.26
Feb 22, 2024 4.30 -0.03 -0.69% 4.33 4.34 4.25
Feb 21, 2024 4.31 -0.02 -0.46% 4.33 4.36 4.23
Feb 20, 2024 4.34 -0.02 -0.46% 4.36 4.58 4.31
Feb 16, 2024 4.37 0.02 0.46% 4.35 4.58 4.28
Feb 15, 2024 4.35 0.10 2.35% 4.25 4.41 4.20
Feb 14, 2024 4.23 0.15 3.68% 4.08 4.26 4.08
Feb 13, 2024 4.04 -0.11 -2.65% 4.15 4.20 4.00
Feb 12, 2024 4.31 0.15 3.61% 4.16 4.43 4.07
Feb 9, 2024 4.15 0.14 3.49% 4.01 4.16 3.86
Feb 8, 2024 4.05 0.44 12.19% 3.61 4.38 3.61
Feb 7, 2024 3.61 -0.08 -2.17% 3.69 3.70 3.58
Feb 6, 2024 3.71 0.27 7.85% 3.44 3.75 3.44
Feb 5, 2024 3.45 -0.14 -3.90% 3.59 3.61 3.44

Vanda Events

Time (UTC) Country Event
Wednesday, May 1, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Vanda Pharmaceuticals Inc Earnings Release
Q1 2024 Vanda Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Friday, June 7, 2024

Time (UTC)

13:00

Country

US

Event

Vanda Pharmaceuticals Inc Annual Shareholders Meeting
Vanda Pharmaceuticals Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 254.382 268.682 248.168 227.188 193.118
Revenue 254.382 268.682 248.168 227.188 193.118
Cost of Revenue, Total 24.282 25.629 23.364 24.488 20.508
Gross Profit 230.1 243.053 224.804 202.7 172.61
Total Operating Expense 248.053 226.517 220.929 204.378 171.38
Selling/General/Admin. Expenses, Total 136.485 124.047 140.51 129.736 105.751
Research & Development 85.77 55.563 48.677 48.649 43.594
Depreciation / Amortization 1.516 1.478 1.478 1.505 1.527
Operating Income 6.329 42.165 27.239 22.81 21.738
Other, Net 4.971 0.199 4.416 6.218 3.608
Net Income Before Taxes 11.3 42.364 31.655 29.028 25.346
Net Income After Taxes 6.275 33.152 23.337 115.553 25.208
Net Income Before Extra. Items 6.275 33.152 23.337 115.553 25.208
Net Income 6.275 33.152 23.337 115.553 25.208
Income Available to Common Excl. Extra. Items 6.275 33.152 23.337 115.553 25.208
Income Available to Common Incl. Extra. Items 6.275 33.152 23.337 115.553 25.208
Diluted Net Income 6.275 33.152 23.337 115.553 25.208
Diluted Weighted Average Shares 56.9832 56.9218 55.1908 54.8471 53.0453
Diluted EPS Excluding Extraordinary Items 0.11012 0.58241 0.42284 2.10682 0.47522
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS 0.11012 0.85462 0.51501 2.10682 0.47522
Unusual Expense (Income) 19.8 6.9
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 46.056 62.498 64.482 65.318 64.39
Revenue 46.056 62.498 64.482 65.318 64.39
Cost of Revenue, Total 3.499 4.774 6.238 6.32 6.059
Gross Profit 42.557 57.724 58.244 58.998 58.331
Total Operating Expense 48.923 60.494 57.853 61.41 60.929
Selling/General/Admin. Expenses, Total 28.399 36.104 32.782 29.854 33.001
Research & Development 16.647 19.237 18.454 24.857 21.49
Depreciation / Amortization 0.378 0.379 0.379 0.379 0.379
Operating Income -2.867 2.004 6.629 3.908 3.461
Other, Net 5.459 3.524 2.984 1.553 0.329
Net Income Before Taxes 2.592 5.528 9.613 5.461 3.79
Net Income After Taxes 1.52 3.252 6.861 3.27 2.574
Net Income Before Extra. Items 1.52 3.252 6.861 3.27 2.574
Net Income 1.52 3.252 6.861 3.27 2.574
Income Available to Common Excl. Extra. Items 1.52 3.252 6.861 3.27 2.574
Income Available to Common Incl. Extra. Items 1.52 3.252 6.861 3.27 2.574
Diluted Net Income 1.52 3.252 6.861 3.27 2.574
Diluted Weighted Average Shares 57.5356 57.4002 58.7393 56.969 56.821
Diluted EPS Excluding Extraordinary Items 0.02642 0.05665 0.1168 0.0574 0.0453
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.02642 0.05665 0.1168 0.0574 0.0453
Unusual Expense (Income)
Other Operating Expenses, Total
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 519.292 478.301 409.145 354.136 299.132
Cash and Short Term Investments 466.859 432.813 367.74 312.129 257.36
Cash & Equivalents 135.029 52.071 61.031 45.072 61.005
Short Term Investments 331.83 380.742 306.709 267.057 196.355
Total Receivables, Net 33.512 32.467 30.036 26.367 28.78
Accounts Receivable - Trade, Net 33.512 32.467 30.036 26.367 28.78
Total Inventory 1.194 1.025 1.28 1.14 0.994
Prepaid Expenses 17.727 11.996 10.032 14.5 11.998
Other Current Assets, Total 0 0 0.057 0
Total Assets 634.247 593.792 533.456 483.748 332.13
Property/Plant/Equipment, Total - Net 10.973 12.385 14.595 15.044 4.417
Property/Plant/Equipment, Total - Gross 21.392 21.762 22.623 21.656 9.636
Accumulated Depreciation, Total -10.419 -9.377 -8.028 -6.612 -5.219
Intangibles, Net 18.565 20.081 21.559 23.037 24.542
Other Long Term Assets, Total 85.417 83.025 88.157 91.531 4.039
Total Current Liabilities 91.436 74.419 65.936 59.505 53.015
Accounts Payable 4.979 5.873 5.817 5.904 5.172
Accrued Expenses 86.457 68.546 59.769 53.601 47.643
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 107.049 88.864 80.19 72.803 56.708
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 15.613 14.445 14.254 13.298 3.693
Total Equity 527.198 504.928 453.266 410.945 275.422
Common Stock 0.057 0.056 0.055 0.054 0.052
Additional Paid-In Capital 686.235 669.223 650.3 631.307 611.587
Retained Earnings (Accumulated Deficit) -157.901 -164.176 -197.328 -220.665 -336.218
Other Equity, Total -0.007 0.032 0.081 0.013 0.001
Total Liabilities & Shareholders’ Equity 634.247 593.792 533.456 483.748 332.13
Total Common Shares Outstanding 56.7838 55.9009 54.8651 53.5496 52.4776
Other Current Liabilities, Total 0 0.35 0 0.2
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Unrealized Gain (Loss) -1.186 -0.207 0.158 0.236
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 536.572 533.504 533.707 519.292 507.106
Cash and Short Term Investments 489.858 489.351 501.496 466.859 454.791
Cash & Equivalents 183.186 150.031 354.171 135.029 49.397
Short Term Investments 306.672 339.32 147.325 331.83 405.394
Total Receivables, Net 29.272 33.621 24.513 33.512 29.352
Accounts Receivable - Trade, Net 29.272 33.621 24.513 33.512 29.352
Total Inventory 1.006 1.08 1.105 1.194 1.59
Prepaid Expenses 16.436 9.452 6.593 17.727 21.373
Other Current Assets, Total 0 0
Total Assets 641.605 641.682 644.532 634.247 621.788
Property/Plant/Equipment, Total - Net 9.556 9.946 10.43 10.973 10.856
Intangibles, Net 17.428 17.808 18.186 18.565 18.944
Other Long Term Assets, Total 78.049 80.424 82.209 85.417 84.882
Total Current Liabilities 84.837 87.397 93.794 91.436 92.623
Accounts Payable 2.28 2.736 3.421 4.979 5.585
Accrued Expenses 82.557 84.661 90.373 86.457 87.038
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total
Total Liabilities 98.505 101.784 108.793 107.049 106.131
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 13.668 14.387 14.999 15.613 13.508
Total Equity 543.1 539.898 535.739 527.198 515.657
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.058 0.057 0.057 0.057 0.057
Additional Paid-In Capital 697.001 693.835 690.586 686.235 681.847
Retained Earnings (Accumulated Deficit) -152.992 -153.129 -154.649 -157.901 -164.762
Unrealized Gain (Loss) -0.954 -0.257 -1.186 -1.434
Other Equity, Total -0.013 -0.865 0.002 -0.007 -0.051
Total Liabilities & Shareholders’ Equity 641.605 641.682 644.532 634.247 621.788
Total Common Shares Outstanding 57.5295 57.4969 57.441 56.7838 56.5886
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 6.275 33.152 23.337 115.553 25.208
Cash From Operating Activities 31.984 64.214 51.775 45.947 29.986
Cash From Operating Activities 1.217 1.363 1.386 1.387 1.429
Amortization 1.516 1.478 1.478 1.505 1.527
Non-Cash Items 15.772 18.739 15.068 12.144 9.612
Changes in Working Capital 6.074 2.737 4.317 3.125 -7.79
Cash From Investing Activities 49.925 -76.696 -41.499 -68.309 -109.66
Capital Expenditures -0.679 -0.552 -1.795 -1.019 -25.368
Other Investing Cash Flow Items, Total 50.604 -76.144 -39.704 -67.29 -84.292
Cash From Financing Activities 0.734 3.55 5.634 6.264 107.126
Issuance (Retirement) of Stock, Net 0.734 3.55 5.634 6.264 107.126
Foreign Exchange Effects 0.265 -0.091 0.053 -0.001 -0.038
Net Change in Cash 82.908 -9.023 15.963 -16.099 27.414
Deferred Taxes 1.13 6.745 6.189 -87.767
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 3.252 6.275 -0.586 -3.856 -6.43
Cash From Operating Activities 31.803 31.984 22.568 9.731 4.046
Cash From Operating Activities 0.291 1.217 0.933 0.634 0.323
Amortization 0.379 1.516 1.137 0.758 0.379
Deferred Taxes 2.014 1.13 0.713 2.55 4.417
Non-Cash Items 3.827 15.772 12.948 9.581 5.407
Changes in Working Capital 22.04 6.074 7.423 0.064 -0.05
Cash From Investing Activities 187.294 49.925 -25.503 -3.726 10.866
Capital Expenditures -0.051 -0.679 -0.416 -0.268 -0.075
Other Investing Cash Flow Items, Total 187.345 50.604 -25.087 -3.458 10.941
Cash From Financing Activities 0.734 0.129 0.125 0
Issuance (Retirement) of Stock, Net 0.734 0.129 0.125 0
Foreign Exchange Effects 0.045 0.265 0.082 0.022 -0.057
Net Change in Cash 219.142 82.908 -2.724 6.152 14.855
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
BlackRock Institutional Trust Company, N.A. Investment Advisor 16.5299 9506119 263036 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 7.272 4182057 109322 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 7.0957 4080636 -471276 2023-06-30 LOW
Renaissance Technologies LLC Hedge Fund 5.4115 3112067 176842 2023-06-30 HIGH
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 3.3897 1949383 -834307 2023-06-30 LOW
Goldman Sachs Asset Management, L.P. Investment Advisor 2.8257 1625048 403220 2023-06-30 LOW
Assenagon Asset Management S.A. Investment Advisor 2.7608 1587717 0 2023-06-30 HIGH
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 2.7217 1565209 347392 2023-06-30 LOW
Polymeropoulos (Mihael Hristos) Individual Investor 2.5681 1476902 0 2023-04-17 LOW
Two Sigma Investments, LP Hedge Fund 2.2515 1294784 209128 2023-06-30 HIGH
D. E. Shaw & Co., L.P. Hedge Fund 2.2283 1281478 -81619 2023-06-30 MED
Hotchkis and Wiley Capital Management, LLC Investment Advisor 2.1823 1255000 223140 2023-06-30 LOW
Acadian Asset Management LLC Investment Advisor/Hedge Fund 1.9807 1139091 100249 2023-06-30 MED
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.9735 1134924 52393 2023-06-30 LOW
Federated MDTA LLC Investment Advisor/Hedge Fund 1.7986 1034328 -10449 2023-06-30 HIGH
PGIM Quantitative Solutions LLC Investment Advisor 1.6781 965070 110861 2023-06-30 LOW
Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 1.4594 839305 -87153 2023-06-30 MED
Columbia Threadneedle Investments (US) Investment Advisor/Hedge Fund 1.4344 824889 -12433 2023-06-30 LOW
Bridgeway Capital Management, LLC Investment Advisor 1.2765 734075 45738 2023-06-30 MED
Charles Schwab Investment Management, Inc. Investment Advisor 1.1095 638072 5715 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Vanda Company profile

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its commercial portfolio consists of two products, HETLIOZ (tasimelteon) for the treatment of jet lag disorder, pediatric non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD), and Fanapt (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia. Its other product pipeline includes Tradipitant (VLY-686), VTR-297, VSJ-110 and BPO-27. VLY-686, is for the treatment of gastroparesis, motion sickness, atopic dermatitis and COVID-19 pneumonia. VTR-297, is for the treatment of hematologic malignancies. VSJ-110, is for the treatment of dry eye and ocular inflammation. BPO-27, is for the treatment of secretory diarrhea disorders, including cholera. Its other product includes VQW-765.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Vanda Pharmaceuticals Inc. revenues increased 8% to $268.7M. Net income increased 42% to $33.2M. Revenues reflect Hetlioz segment increase of 8% to $173.5M, Fanapt segment increase of 9% to $95.1M. Net income benefited from Selling, General and administrative - decrease of 10% to $105.9M (expense), Advertising Expenses decrease of 47% to $6.7M (expense).

Equity composition

Common Stock $.001 Par, 04/11, 150M auth., 28,103,441 issd. Insiders own 1.56%. 4/18/06 IPO: 5.8M shs. @ $10 per shareby JP Morgan Securities, Inc.

Industry: Bio Therapeutic Drugs

Suite 300E
2200 Pennsylvania Ave Nw
WASHINGTON
WASHINGTON DC 20037
US

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

Oil - Crude

78.04 Price
-0.540% 1D Chg, %
Long position overnight fee 0.0260%
Short position overnight fee -0.0479%
Overnight fee time 22:00 (UTC)
Spread 0.030

XRP/USD

0.65 Price
-1.020% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

67,237.15 Price
-0.360% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Gold

2,117.43 Price
+0.090% 1D Chg, %
Long position overnight fee -0.0189%
Short position overnight fee 0.0107%
Overnight fee time 22:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading